Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASIS: Cefetamet Pivoxil in Sinusitis
NCT04664803Phase 4Terminated
- Sponsor
- Korea United Pharm Inc.
- Start
- Aug 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of cefetamet pivoxil in acute sinusitis (2 arms), sponsored by Korea United Pharm Inc. Primary endpoint: Clinical effective rate at 21 days. Started Aug 2015; status: terminated.
02
Drugs
cefetamet pivoxil
03
Conditions
acute sinusitis
Beyond the preview
Go deeper on NCT04664803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04664803.